Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107

BACKGROUND: Papillary renal cell carcinoma (pRCC) is associated with EGFR expression and activation of MET signaling pathway. A randomized multicenter parallel two-stage phase II trial of MET inhibitor tivantinib alone or in combination with EGFR inhibitor erlotinib was conducted in patients with pR...

Descripción completa

Detalles Bibliográficos
Autores principales: Twardowski, Przemyslaw W., Tangen, Catherine M., Wu, Xiwei, Plets, Melissa R., Plimack, Elizabeth R., Agarwal, Neeraj, Vogelzang, Nicholas J., Wang, Jinhui, Tao, Shu, Thompson, Ian M., Lara, Primo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179121/
https://www.ncbi.nlm.nih.gov/pubmed/30334014
http://dx.doi.org/10.3233/KCA-170018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179121/
https://www.ncbi.nlm.nih.gov/pubmed/30334014
http://dx.doi.org/10.3233/KCA-170018

Ejemplares similares